| Bueno, Godoy and Suzuki3535. Bueno RLP, Godoy MR, Suzuki C. Brazilian national guideline for multiple sclerosis (MS): an exploratory study about the impact of the patient's adherence in the treatment costs. Value Health. 2009;12:197-198.
|
2007
|
Sao Paulo/
Brazil
|
-DMD used in Sao Paulo
-Adherence to DMD in Sao Paulo
-Treatment cost of DMD |
Total adherence 34.4%
-Treatment distribution: IFN-1a (two brands) 60.66%, IFN-1b
20.5% and GA 18.85%
-Adherence per treatment: GA 36.9%, IFN-1a (two brands) 33.67% and IFN-1b
32.3%
-Annual costs per patient treated was USD 27,824 for GA, USD 42,151 for
IFN-1a (two brands) and USD 34,038 for IFN-1b
-Total treatment costs higher than USD 92 million
per year |
| Ferreira da Silva et al.3636. Ferreira da Silva AL, Filkelsztejn A, Ribeiro R, Polanczyk CA. Value of budget impact analysis based on epidemiologic data: insights from multiple sclerosis in Sao Paulo, Brazil. Value Health 2010;13:388.
|
2009
|
Sao Paulo
/Brazil
|
-Currently treated MS cases for Sao Paulo
-Total cost of currently treated MS cases for Sao Paulo |
-1319 patients under treatment
-Prevalence of 11.9 cases per 100,000 inhabitants of RRMS cases treated
-Actual costs of all patients treated in Sao Paulo for 2009 was USD 23,433,100
|
| Takemoto, Takemoto and Fernandes30-32
|
2006-2009
|
Rio de Janeiro/
Brazil
|
-Causes of admission to hospital for MS patients
-Length of hospitalisation of MS patients
-Mean intensive care unit days of MS patients
-In-hospital mortality
-Mean cost per hospitalisation |
-Annual hospitalisations due to MS were 1936 episodes, per year
-91% of hospitalisations were for RRMS patients
-The mean rates of mortality were 2.5% per year in RRMS patients
-Mean length of hospitalisation was 8.9 days
-Average cost per hospitalisation was USD 358
-Total expenditure with MS inpatient admission was USD 651,977
-Relapses were responsible for 90% of admissions in the population evaluated
|
| Study |
Year
|
City/
Country
|
Outcomes evaluated |
Results/Comments |
| Takemoto, Takemoto and Fernandes30-32
|
2006-2009
|
Brazil
|
-Patients under MS treatment in Brazil from 2006-2009
-Described treatment used for MS in 27 states of Brazil |
-2006 with 3569 patients under treatment
-2009 with 6099 patients under treatment
-The probability of the use of GA was:
9.5% in 2006, 20.1% in 2007, 20.7% in 2008 and 21.3% in 2009
-The probability of use of IFNβ1a 22 mcg was 17.3% for 2006 and 11.4%
for 2009
-The probability of use of IFNβ1a 44 mcg, IFNβ1b and IFNβ1a
30 mcg, was 20% to 25 % across the
4 years |
| Takemoto, Takemoto and Fernandes30-32
|
2006-2009
|
Brazil
|
-Expenditures with MS treatment in 27 states of Brazil |
-MS public expenditures with drugs was USD 14,011,700
-MS public expenditure with drugs was USD 122,575,000 in 2009
-Total investment in MS drugs was USD 360,124,000 in 2009 |
| Gonorazky3333. Gonorazky S. Tratamiento de la esclerosis múltiple con los interferones beta y el acetato de glatiramer: evaluación del costo relacionado a la eficacia en Argentina, Estados Unidos y Gran Bretaña. Rev Neurol Argentina. 2004;29:24-29.
|
2004
|
Argentina
|
-Costs of DMD in Argentina per year for 2004 |
-Cost of GA, per year, in Argentina was USD 35,280 for 2004
-Cost of IFNβ1b, per year, was USD 31,548 for 2004
-Cost of IFNβ1a 44 mcg, per year, was USD 43,080 for 2004
-Cost of IFNβ1a 30 mcg, per year, was USD 29,256 for 2004 |
| Romero et al.3434. Romero M, Arango C, Alvis N, Suarez JC, Duque A. The cost of treatment of multiple sclerosis in Colombia. Value Health 2011;14:48-50.
|
2003-2008
|
Colombia
|
-Third payer perspective
-Direct costs (DMD, hospitalisations, consults, relapses and time of relapses)
in Colombia
-Indirect costs (disability and caregivers)
-Differential costs by EDSS (0 to 2.5-3, 2.5-3 to 5.5-6, 5.5-6 to 7.5-8
and 7.5-8 to 9.5) |
Phase I of the disease (EDSS 0-2.5)
-Direct cost on Phase I of the disease was USD 1,191,630 (2008), GA 3.1%,
without DMD (USD 502,384)
-Direct cost with DMD on Phase I was USD 35,964,316 (2008), COP 92.7% (USD
15,162,316)
-Indirect cost on Phase I was USD 1,626,516, COP 4.2% (USD 685,729)
-Total cost for third payer on Phase I of the disease was USD 38,782,462,
GA (USD 16, 350,570)
Phase II (EDSS 3-5.5)
-Direct cost on Phase II of the disease was USD 2,714,554 (2008), GA 5.4%,
without DMD (USD 1,144,443)
-Direct cost with DMD on Phase II was USD 45,862,278 (2008), GA 90.7% (USD
19,335,876)
-Indirect cost on Phase II was USD 2,004,372, COP 4% (USD 845,031)
-Total cost for third payer on Phase I of the disease was USD 50,581,204,
GA (USD 21, 324,765)
Phase III (EDSS 6-7.5)
-Direct cost on Phase III of the disease was USD 1,505,988 (2008), COP 4.2%,
without DMD (USD 634,916)
-Direct cost with DMD on Phase III was USD 32,686,563 (2008), GA 91.1% (USD
13,780,500)
-Indirect cost on Phase III was USD 1,706,868, COP 4.8% (USD 298,011)
-Total cost for third payer on Phase I of the disease was USD 35,899,419,
GA (USD 15,135,000)
Phase IV (EDSS 8-9.5)
-Direct cost on Phase IV of the disease was USD 561,293 (2008), COP 2.7%,
without DMD (USD 236,638)
-Direct cost with DMD on Phase IV was USD 12,077,550 (2008), GA 58.2% (USD
5,091,088)
-Indirect cost on Phase IV was USD 8,100,000, GA 39.1% (3,414,000 USD)
-Total cost for third payer on Phase I of the disease was USD 20,738,843,
GA (USD 8,743,370) |
